Original article
A comparison of two Quality-of-Life Questionnaires for cancer clinical trials: The Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core module (QLQ-C30)

https://doi.org/10.1016/0895-4356(96)89258-4Get rights and content

Abstract

Choosing a measuring instrument for a study raises the question of whether instruments designed for the same purpose produce the same results. We investigated this question for two instruments designed to measure subjective quality of life (QOL) in cancer clinical trials: the Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core module (QLQ-C30). These were administered concurrently to 98 cancer patients. Four patient groups were defined: (1) well, no chemotherapy (n = 23); (2) adjuvant chemotherapy (n = 24); (3) stable disease, active chemotherapy (n = 24); (4) progressive disease (n = 27). Both instruments have global, role, social, emotional, pain, and nausea scales; QLQ-C30 also assesses physical function, cognitive function, and fatigue, while FLIC assesses hardship. Correlation analysis indicated convergent validity for the global, role, emotional, pain, and nausea dimensions, but not the social dimension. Both instruments indicated that groups 1 and 2 had better QOL than group 4 in at least one dimension. However, different dimension-specific results meant that qualitatively different conclusions would have been drawn if either instrument had been used singly: FLIC indicated that group 1 had better role function than group 4 and suffered less hardship and that group 1 suffered less nausea than group 3, while the QLQ-C30 data indicated that group 2 had better physical function than group 4. The only consistent result was for pain: both instruments indicated group 4 had more pain than either groups 1 or 2. Thus the choice of QOL instrument for use in a particular trial will affect both the results and conclusions. It is important, therefore, to consider carefully which instrument is most likely to detect important differences relevant to the patients' lives in that setting.

References (54)

  • DF Cella et al.

    Quality of life in cancer: definition, purpose, and method of measurement

    Cancer Investigation

    (1993)
  • L Fallowfield

    The quality of life in cancer

  • H Schipper et al.

    Assessment of treatment in cancer

  • NK Aaronson et al.

    The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

    J Natl Cancer Inst

    (1993)
  • GH Guyatt et al.

    Issues in quality of life measurement in clinical trials

    Controlled Clinical Trials

    (1991)
  • R Jaeschke et al.

    How to develop and validate a new quality of life instrument

  • KN Lohr
  • SJ Pocock

    A perspective on the role of quality-of-life assessment in clinical trials

    Contr Clin Trials

    (1991)
  • A Clark et al.

    Quality of life measurements in patients with malignant disease: a review

    J Royal Soc Med

    (1986)
  • K Donovan et al.

    Measuring quality of life in cancer patients

    J Clin Oncol

    (1989)
  • P Maguire et al.

    Assessing quality of life in cancer patients

    Br J Cancer

    (1989)
  • P Selby et al.

    Measurement of quality of life of patients with cancer

    Cancer Surveys

    (1987)
  • D Osoba et al.

    A practical guide for selecting quality-of-life measures in clinical trials and practice

  • H Schipper et al.

    Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

    J Clin Oncol

    (1984)
  • R Feld

    Quality of life assessment in patients with carcinoma of the lung

    Chest

    (1989)
  • NK Aaronson et al.

    The EORTC core quality-of-life questionnaire: interim results of an international field study

  • GR Morrow et al.

    Measurement of quality of life in patients: psychometic analyses of the Functional Living Index-Cancer (FLIC)

    Qual Life Res

    (1992)
  • Cited by (48)

    • Systematic review recommends the European Organization for Research and Treatment of Cancer colorectal cancer-specific module for measuring quality of life in colorectal cancer patients

      2015, Journal of Clinical Epidemiology
      Citation Excerpt :

      The rest of them were rated as unknown, and one item (Quality-Quantity Questionnaire [43]) was rated as limited negative. Thirty-two instruments were rated on this property with 11 rated as strong positive (version 1 of QLQ-C30 [28,64], version 3 of QLQ-C30 [5,27,30,65,66], QLQ-CR38 [21–27], QLQ-LMC21 [46,50], version 4 of FACT-G [23,27,69], FACT-C [23,27,33,34,55,59–61], FCSI-9 [35], FACIT-F [68], QLICP-CR [62], MSKCC Bowel Function [40,41], and EQ-5D [72]). All ratings given to the nine instruments that were assessed on this property (version 3 of QLQ-C30 [27,29,30,65,66], QLQ-SWB36 [53], QLQ-CR38 [21–27], QLQ-CR29 [31,54], FACT-C [23,27,33,34,55,59–61], MSAS-SF [56], CMSAS [56], SRQS [57], and MSKCC Bowel Function [40,41]) were unknown as inadequate information was provided by these studies.

    • The value of quality of life and health status measurements in the evaluation of the well-being of breast cancer survivors

      2008, European Journal of Surgical Oncology
      Citation Excerpt :

      The aim of this study was to determine whether the scores on QoL and HS of breast cancer survivors were comparable to scores of healthy reference populations and to establish the difference in conclusions reached when applying a QoL questionnaire compared with a HS questionnaire. Previous studies have compared different HS questionnaires to see whether the results are interchangeable when applied to cancer patients.24,25,26,27 All studies showed considerable differences in outcomes between the questionnaires used.

    View all citing articles on Scopus

    This research was supported by a scholarship from the Public Health Research and Development Committee of the National Health and Medical Research Council of Australia.

    View full text